Related Experiment Video

Updated: Jun 19, 2025

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

17.9K

The molecular mechanism underlying KRAS regulation on STK31 expression in pancreatic ductal adenocarcinoma

Yuting Liu1,2, Shing Chun Tang1, Chi Han Li1

  • 1School of Biomedical Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China.

Cancer Science
|July 26, 2024
PubMed

Insights

Targeting serine/threonine kinase 31 (STK31) shows promise for KRAS-mutant pancreatic ductal adenocarcinoma (PDAC). STK31, regulated by KRAS/MAPK/ERK/c-Jun signaling, drives PDAC growth by affecting cell cycle regulators.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Genetics

Background:

  • KRAS mutations are prevalent in pancreatic ductal adenocarcinoma (PDAC), presenting a significant therapeutic challenge.
  • Identifying novel therapeutic targets within KRAS-mutant PDAC is crucial for improving patient outcomes.

Purpose of the Study:

  • To screen for and characterize novel kinases involved in KRAS-driven PDAC.
  • To investigate serine/threonine kinase 31 (STK31) as a potential therapeutic target in KRAS-mutant PDAC.

Main Methods:

  • Utilized an endoribonuclease-prepared small interfering RNA (esiRNA) library for kinase screening.
  • Employed in vitro and in vivo models, gain/loss of function experiments, and pharmacological inhibition assays.
  • Investigated signaling pathways (MAPK/ERK, c-Jun) and downstream targets (CCNB1, CDC25C) using RNA sequencing.

Main Results:

  • STK31 was identified as a kinase upregulated in KRAS-mutant PDAC with poor survival and highly expressed in KRASG12D-mutant PDAC cell lines.
  • Inhibition of STK31 reduced PDAC cell growth in vitro and tumor growth in vivo.
  • Mechanistic studies revealed STK31 as a downstream target of KRAS/MAPK/ERK/c-Jun signaling, directly modulating cell cycle regulators CCNB1 and CDC25C.

Conclusions:

  • STK31 is a key downstream effector of the KRAS/MAPK/ERK/c-Jun pathway in KRAS-mutant PDAC.
  • STK31 promotes PDAC progression by regulating cell cycle genes CCNB1 and CDC25C.
  • STK31 represents a promising therapeutic target for KRAS-mutant pancreatic cancer.
Keywords:
KRASSTK31kinasepancreatic cancertherapeutic target

More Related Videos

Mimicking and Manipulating Pancreatic Acinar-to-Ductal Metaplasia in 3-dimensional Cell Culture08:16

Mimicking and Manipulating Pancreatic Acinar-to-Ductal Metaplasia in 3-dimensional Cell Culture

Published on: February 11, 2019

8.7K
Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets07:08

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets

Published on: February 2, 2024

773

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.5K
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
6.2K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
8.8K
Small GTPases - Ras and Rho01:24

Small GTPases - Ras and Rho

Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
3.9K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
5.4K